These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

685 related items for PubMed ID: 26377051

  • 21. Attitudes and Beliefs About New Psychoactive Substance Use Among Electronic Dance Music Party Attendees.
    Palamar JJ, Acosta P, Cleland CM.
    Subst Use Misuse; 2018 Feb 23; 53(3):381-390. PubMed ID: 28777688
    [Abstract] [Full Text] [Related]

  • 22. Shifting characteristics of ecstasy users ages 12-34 in the United States, 2007-2014.
    Palamar JJ, Mauro PM, Han BH, Martins SS.
    Drug Alcohol Depend; 2017 Dec 01; 181():20-24. PubMed ID: 29028555
    [Abstract] [Full Text] [Related]

  • 23. Next generation of novel psychoactive substances on the horizon - A complex problem to face.
    Zawilska JB, Andrzejczak D.
    Drug Alcohol Depend; 2015 Dec 01; 157():1-17. PubMed ID: 26482089
    [Abstract] [Full Text] [Related]

  • 24. Lifetime prevalence of novel psychoactive substances use among adults in the USA: Sociodemographic, mental health and illicit drug use correlates. Evidence from a population-based survey 2007-2014.
    Neicun J, Yang JC, Shih H, Nadella P, van Kessel R, Negri A, Czabanowska K, Brayne C, Roman-Urrestarazu A.
    PLoS One; 2020 Dec 01; 15(10):e0241056. PubMed ID: 33125395
    [Abstract] [Full Text] [Related]

  • 25. Novel psychoactive substance and other drug use by young adults in Western australia.
    Goggin LS, Gately N, Bridle RI.
    J Psychoactive Drugs; 2015 Dec 01; 47(2):140-8. PubMed ID: 25950594
    [Abstract] [Full Text] [Related]

  • 26. A qualitative descriptive analysis of effects of psychedelic phenethylamines and tryptamines.
    Palamar JJ, Acosta P.
    Hum Psychopharmacol; 2020 Jan 01; 35(1):e2719. PubMed ID: 31909513
    [Abstract] [Full Text] [Related]

  • 27. Examination of Synthetic Cannabinoid and Cathinone Use among a Drug-Using Offender Sample, 2013-2015.
    Smith KE, Bunting AM, Staton M, Walker R, Shalash S, Winston E, Pangburn K.
    J Psychoactive Drugs; 2017 Jan 01; 49(5):436-445. PubMed ID: 28813207
    [Abstract] [Full Text] [Related]

  • 28. Festivals following the easing of COVID-19 restrictions: Prevalence of new psychoactive substances and illicit drugs.
    Rousis N, Bade R, Romero-Sánchez I, Mueller JF, Thomaidis NS, Thomas KV, Gracia-Lor E.
    Environ Int; 2023 Aug 01; 178():108075. PubMed ID: 37399770
    [Abstract] [Full Text] [Related]

  • 29. The users of Novel Psychoactive Substances: Online survey about their characteristics, attitudes and motivations.
    Soussan C, Kjellgren A.
    Int J Drug Policy; 2016 Jun 01; 32():77-84. PubMed ID: 27184218
    [Abstract] [Full Text] [Related]

  • 30. Self-Reported Ecstasy/MDMA/"Molly" Use in a Sample of Nightclub and Dance Festival Attendees in New York City.
    Palamar JJ, Acosta P, Ompad DC, Cleland CM.
    Subst Use Misuse; 2017 Jan 02; 52(1):82-91. PubMed ID: 27661470
    [Abstract] [Full Text] [Related]

  • 31. Characteristics of the use of 3-MMC and other new psychoactive drugs in Slovenia, and the perceived problems experienced by users.
    Sande M.
    Int J Drug Policy; 2016 Jan 02; 27():65-73. PubMed ID: 25908121
    [Abstract] [Full Text] [Related]

  • 32. The drug situation in Europe: an overview of data available on illicit drugs and new psychoactive substances from European monitoring in 2015.
    Mounteney J, Griffiths P, Sedefov R, Noor A, Vicente J, Simon R.
    Addiction; 2016 Jan 02; 111(1):34-48. PubMed ID: 26419329
    [Abstract] [Full Text] [Related]

  • 33. New psychoactive substances in Turkey: Narcotics cases assessed by the Council of Forensic Medicine between 2016 and 2017 in Ankara, Turkey.
    Göl E, Çok I.
    Forensic Sci Int; 2019 Jan 02; 294():113-123. PubMed ID: 30502695
    [Abstract] [Full Text] [Related]

  • 34. New Psychoactive Substances and Suicidality: A Systematic Review of the Current Literature.
    Chiappini S, Mosca A, Miuli A, Santovito MC, Orsolini L, Corkery JM, Guirguis A, Pettorruso M, Martinotti G, Di Giannantonio M, Schifano F.
    Medicina (Kaunas); 2021 Jun 06; 57(6):. PubMed ID: 34204131
    [Abstract] [Full Text] [Related]

  • 35. Psychoactive substances--some new, some old: a scan of the situation in the U.S.
    Maxwell JC.
    Drug Alcohol Depend; 2014 Jan 01; 134():71-77. PubMed ID: 24140401
    [Abstract] [Full Text] [Related]

  • 36. Novel psychoactive substances.
    Krabseth HM, Tuv SS, Strand MC, Karinen RA, Wiik E, Vevelstad MS, Westin AA, Øiestad EL, Vindenes V.
    Tidsskr Nor Laegeforen; 2016 May 01; 136(8):714-7. PubMed ID: 27143461
    [Abstract] [Full Text] [Related]

  • 37. A cross-sectional emergency department survey of novel psychoactive substance prevalence.
    Fockele C, Armenian P.
    Am J Emerg Med; 2017 Oct 01; 35(10):1580. PubMed ID: 28549581
    [No Abstract] [Full Text] [Related]

  • 38. Identification of novel psychoactive drug use in Sweden based on laboratory analysis--initial experiences from the STRIDA project.
    Helander A, Beck O, Hägerkvist R, Hultén P.
    Scand J Clin Lab Invest; 2013 Aug 01; 73(5):400-6. PubMed ID: 23692208
    [Abstract] [Full Text] [Related]

  • 39. Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling.
    Liechti M.
    Swiss Med Wkly; 2015 Aug 01; 145():w14043. PubMed ID: 25588018
    [Abstract] [Full Text] [Related]

  • 40. Increased intensity of Ecstasy and polydrug usage in the more experienced recreational Ecstasy/MDMA users: a WWW study.
    Scholey AB, Parrott AC, Buchanan T, Heffernan TM, Ling J, Rodgers J.
    Addict Behav; 2004 Jun 01; 29(4):743-52. PubMed ID: 15135556
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.